Trupanion Inc header image

Trupanion Inc

TRUP

Equity

ISIN null / Valor 24738737

NASDAQ (2026-04-17)
USD 28.20+1.62%

Trupanion Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Trupanion Inc, established in 2000, specializes in providing medical insurance plans for cats and dogs through a direct-to-consumer, subscription-based model. Operating in the United States, Canada, and Puerto Rico, the company offers comprehensive coverage that helps pet owners manage veterinary expenses by reimbursing eligible medical costs. Trupanion utilizes technology and data analytics to enhance the insurance process, aiming to deliver efficient and reliable services within the pet insurance market. By focusing on customer-centric solutions, Trupanion serves as a key player in ensuring pets receive necessary medical care without the financial burden on their owners.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.04.2026):

Trupanion Inc — fourth quarter of 2025: Trupanion reported Q4 2025 results showing revenue and profitability growth as subscription revenue and margins expanded. Total Q4 revenue was $376.9M (+12% y/y), subscription revenue was $261.4M (+15% y/y), and net income was $5.6M ($0.13 per share) versus $1.7M a year earlier. The company also delivered higher adjusted EBITDA, positive operating and free cash flow, and reported full-year 2025 profitability after a 2024 loss.

Revenue

Total revenue for Q4 2025 was $376.9 million, up 12% year-over-year. Subscription revenue in Q4 was $261.4 million, up 15% y/y. For the full year 2025, total revenue was $1,439.3 million (+12%) and subscription revenue was $989.3 million (+16%).

Profitability & non-GAAP results

Q4 net income was $5.6 million ($0.13 per basic and diluted share) versus $1.7 million in Q4 2024. Adjusted EBITDA for Q4 was $21.8 million (vs. $19.4M a year ago). For FY2025, net income was $19.4 million ($0.45/share) versus a $9.6 million loss in 2024, and adjusted EBITDA was $70.1 million (vs. $46.1M in 2024).

Cash flow & liquidity

Q4 operating cash flow was $29.3 million and free cash flow was $25.3 million (Q4 2024: $23.7M and $21.8M). Full-year operating cash flow was $89.5 million and free cash flow $75.4 million. At December 31, 2025, the company held $370.7 million in cash and short-term investments (including $50.0M outside the insurance entities) and had $5.0M available under its credit facility.

Enrollment, retention & unit economics

Total enrolled pets at December 31, 2025 were 1,647,565 (down 2% y/y). Subscription enrolled pets grew to 1,096,173 (up 5% y/y). Q4 operating metrics: monthly average revenue per pet $83.56, average pet acquisition cost (PAC) $320, and average monthly retention 98.34%.

Margins & segment operating performance

Q4 subscription adjusted operating income was $43.1M, representing a 16.5% margin on subscription revenue (up from 15.3% a year earlier). Total business adjusted operating income for Q4 was $45.0M (11.9% margin).

Management commentary / strategic context

Management highlighted delivery of over $500M in discretionary profit since 2021 and achieving a 15% annual margin target in 2025 while reinvesting record profits to drive higher retention and accelerating gross pet adds, positioning the company for its next strategic plan.

Summarized from source with an LLMView Source

Key figures

-18.8%1Y
-21.7%3Y
-65.3%5Y

Performance

46.7%1Y
70.7%3Y
72.7%5Y

Volatility

Market cap

1225 M

Market cap (USD)

Daily traded volume (Shares)

281,176

Daily traded volume (Shares)

1 day high/low

49.64 / 47.85

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.17%USD 105.98
Tilray Brands Inc
Tilray Brands Inc Tilray Brands Inc Valor: 42386407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.03%USD 6.86
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.91%USD 22.88
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.68%USD 20.57
Envista Holdings Corporation
Envista Holdings Corporation Envista Holdings Corporation Valor: 49153522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.34%USD 27.84
Humana Inc
Humana Inc Humana Inc Valor: 940174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.18%USD 205.14
Inspire Medical Systems Inc
Inspire Medical Systems Inc Inspire Medical Systems Inc Valor: 41329373
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.02%USD 57.59
Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.30%SEK 579.00
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.27%USD 309.66
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc Apellis Pharmaceuticals Inc Valor: 30132056
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 40.90